Guy Jérusalem
- Oncology top 0.2%
- Cancer Treatment and Pharmacology 91
- HER2/EGFR in Cancer Research 80
- Cancer Immunotherapy and Biomarkers 24
- Lung Cancer Research Studies 22
- Cancer Research top 0.5%
- Breast Cancer Treatment Studies 39
- Pulmonary and Respiratory Medicine top 0.5%
- Advanced Breast Cancer Therapies 108
-
- Medical Imaging Techniques and Applications 27
- Pathology and Forensic Medicine top 0.5%
-
- PI3K/AKT/mTOR signaling in cancer 26
Guy Jérusalem
318 papers receiving 8.9k citations
Hit Papers
Peers
Comparison fields: 5 of 144
- Oncology 4.8k
- Cancer Research 1.9k
- Pulmonary and Respiratory Medicine 3.4k
- Radiology, Nuclear Medicine and Imaging 1.8k
- Pathology and Forensic Medicine 1.4k
Countries citing papers authored by Guy Jérusalem
This map shows the geographic impact of Guy Jérusalem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guy Jérusalem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guy Jérusalem more than expected).
Fields of papers citing papers by Guy Jérusalem
This network shows the impact of papers produced by Guy Jérusalem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guy Jérusalem. The network helps show where Guy Jérusalem may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Guy Jérusalem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2023 | 33 | |
| 3 | 2022 | 6 | |
| 4 | 2022 | 11 | |
| 5 | 2020 | 62 | |
| 6 | 2018 | 41 | |
| 7 | Phase Ib/II study evaluating safety and efficacy of Pembrolizumab and Trastuzumab in patients with Trastuzumab-resistant HER2-positive advanced breast cancer : results from the PANACEA study (IBCSG 45-13/BIG 4-13/KEYNOTE-014) | 2017 | 5 |
| 8 | 2016 | 82 | |
| 9 | Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial | 2016 | 1 |
| 10 | A phase 1b study of Trebananib plus Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in patients with HER2+ locally recurrent or metastatic breast cancer | 2015 | 1 |
| 11 | 2014 | 110 | |
| 12 | 2014 | 34 | |
| 13 | Le traitement multidisciplinaire du glioblastome | 2014 | 1 |
| 14 | [The drug of the month: everolimus (Afinitor) for the treatment of metastatic breast cancer]. | 2014 | 2 |
| 15 | Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes | 2014 | 8 |
| 16 | Extended adjuvant letrozole following five years of tamoxifen is cost-effective from a Belgian health care payer's perspective | 2006 | 3 |
| 17 | Whole-Body Positron Emission Tomography using 18F-Fluorodeoxyglucose for Staging Response Assessment in Hodgkin's Disease | 2005 | 1 |
| 18 | Whole-body FDG PET imaging as a method for staging and early assessment of treatment response in pediatric patients with lymphoma. | 2003 | 1 |
| 19 | Early detection of relapse by whole-body positron emission tomography (PET) using 18F-fluorodeoxyglucose (18F-FDG) in the follow-up of patients with Hodgkin’s disease (HD). | 2000 | 5 |
| 20 | PET imaging of liver metastases: a retrospective study. | 1996 | 2 |
About Guy Jérusalem
Guy Jérusalem is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Neuropsychology and Physiological Psychology, having authored 333 papers that have together received 9.1k indexed citations. Recurring topics across this work include Advanced Breast Cancer Therapies (108 papers), Cancer Treatment and Pharmacology (91 papers), HER2/EGFR in Cancer Research (80 papers), Breast Cancer Treatment Studies (39 papers), Medical Imaging Techniques and Applications (27 papers), PI3K/AKT/mTOR signaling in cancer (26 papers), Cancer Immunotherapy and Biomarkers (24 papers) and Lung Cancer Research Studies (22 papers). The work is most often cited by research in Oncology (4.8k citations), Cancer Research (1.9k citations) and Pulmonary and Respiratory Medicine (3.4k citations). Guy Jérusalem has collaborated with scholars based in Belgium, United States and France. Frequent co-authors include Georges Fillet, Yves Béguin, Marie France Fassotte, P. Rigo, Fadi Najjar, Joëlle Collignon, Patrick Paulus, Laurence Lousberg, Hélène Schroeder and R. Hustinx. Their work appears in journals such as Annals of Oncology, Cancer Research, Journal of Clinical Oncology, Breast Cancer Research and Treatment and BMC Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.